Affymetrix and Iconix Co-Develop Comprehensive Toxicogenomics Research Tool.ToxFX[TM] Analysis Suite Helps Researchers Prioritize Drug Candidates and Make Preclinical Development Decisions Faster Than Ever Before SANTA CLARA Santa Clara, city, Cuba Santa Clara (sän`tä klä`rä), city (1994 est. pop. 217,000), capital of Villa Clara prov., central Cuba. & MOUNTAIN VIEW, Calif. -- Affymetrix Inc. (Nasdaq: AFFX) and Iconix Biosciences today announced the launch of the ToxFX[TM] Analysis Suite, a toxicogenomics solution that improves researchers' understanding of safety issues associated with new drug candidates, compounds or environmental toxicants. ToxFX, which combines Iconix' revolutionary automated analysis with Affymetrix' GeneChip([R])arrays, helps scientists prioritize drug candidates and make preclinical development decisions faster than ever before. Obtaining a full compound safety profile using classical toxicology toxicology, study of poisons, or toxins, from the standpoint of detection, isolation, identification, and determination of their effects on the human body. Toxicology may be considered the branch of pharmacology devoted to the study of the poisonous effects of drugs. methods requires a series of individual assays that take weeks or months to perform. The entire ToxFX analysis process can be completed in as little as three days following sample collection, and the report itself is generated and transmitted to the investigator's desktop within minutes after the experiment is finished. "We have consistently heard from the toxicology community that analysis of the data is the single largest barrier to applying toxicogenomics as a standard screening tool in drug development programs," said Don Halbert, Ph.D., executive vice president of Research and Development at Iconix Biosciences. "The ToxFX Analysis Suite offers the distilled toxicogenomic experience of our specialized Iconix scientists and the context of our comprehensive DrugMatrix reference data set in an easy-to-use and affordable product. This will help scientists prioritize drug candidates and make preclinical development decisions quickly and with more relevant information than ever before." To watch a full Affymetrix UserForum interview about the ToxFX Analysis Suite with Iconix' Kurt Jarnagin, Ph.D., and Affymetrix' Iain Russell Iain Russell (born 14 November 1982) is a Scottish semi-professional footballer currently playing at centre-forward for Greenock Morton in the scottish Football League. He was previously at Rangers[1] , Ph.D., please visit: http://www.affymetrix.com/userForum/news/collaborations/ToxFX.uf The new ToxFX Analysis Suite was developed to accelerate the process of obtaining a full compound safety profile by detecting a drug's toxicity at the molecular level. ToxFX brings a toxicogenomic approach to every drug discovery effort, even if researchers do not have access to specialized bioinformatics capabilities. The ToxFX Analysis Suite generates a safety profile that can diagnose or predict more than 50 toxicological outcomes. It also examines the gene expression changes in 22 of the most relevant biological pathways, offering an early understanding of the potential underlying mechanisms of toxicity. "Affymetrix has been working with Iconix Biosciences for the past year to co-develop the ToxFX Analysis Suite, which will revolutionize the drug development process," said Chip Leveille, vice president of the Pharmaceutical Business Unit at Affymetrix. "The ToxFX Analysis Suite combines Affymetrix' gold standard microarray technology with Iconix' expert toxicology database and analytical reports. This is an easy-to-use tool that will help accelerate research and improve the quality of drug candidates." The ToxFX Analysis Suite is a direct result of the collaborative agreement that Affymetrix and Iconix signed in February 2006. Together, Affymetrix' GeneChip expression arrays and Iconix' automated analysis provide detailed information on a drug candidate's toxicological liabilities and pharmacological properties. Researchers perform the molecular analysis by generating gene expression data from rat samples on either the GeneChip Rat ToxFX 1.0 Array or the Rat Genome 230 2.0 Array. The data are then compared to the Iconix Drug Signatures([R]) and pathway response libraries and cross-referenced to identify matches to known toxicological responses. A toxicity profile report is then generated for the compound based on this information. To view the product datasheet, please visit: http://www.affymetrix.com/support/technical/datasheets/toxfx_datasheet .pdf (Due to its length, this URL URL in full Uniform Resource Locator Address of a resource on the Internet. The resource can be any type of file stored on a server, such as a Web page, a text file, a graphics file, or an application program. may need to be copied/pasted into your Internet browser's address field. Remove the extra space if one exists.) The ToxFX Analysis Suite (ToxFX 1.0 GeneChip microarrays with Analysis Certificates) is available from Affymetrix. Additionally, an individual Analysis Certificate, which enables data from a single array to be compared with the reference database, may be purchased directly from Iconix. Analyzing a ToxFX study does not require any prior subscriptions or licensing of either the ToxFX Study Builder software or the DrugMatrix reference database. The Analysis Certificate provides researchers with the flexibility and convenience to decide when and how to perform their toxicology studies. For more information on the ToxFX Analysis Suite, please visit: www.toxfx.com Today, Affymetrix and Iconix are launching the ToxFX Analysis Suite at the American College American College is the name of:
About Iconix Iconix Biosciences Inc., the leader in toxicogenomics products and services, has pioneered the integration of chemistry and genomics to enable the pharmaceutical and other industries to develop safer drug candidates and compounds. The company's technologies increase the odds of advancing the right candidates to the clinic, reduce attrition rates in late-stage trials and help keep the costs of drug discovery in check. Iconix provides reference systems and universally recognized expertise to predict safety liabilities, side effects Side effects Effects of a proposed project on other parts of the firm. and mechanisms of toxicity for drug candidates and environmental chemicals. Iconix' DrugMatrix system has been installed at the U.S. Food and Drug Administration for use by CDER CDER Center for Drug Evaluation and Research (US FDA) CDER Centre de Développement des Energies Renouvelables (French) CDER Client Development and Evaluation Report (Center for Drug Evaluation and Research The Center for Drug Evaluation and Research is a division of the FDA that deals with the approval of drugs. CDER reviews New Drug Applications to ensure that the drugs are safe and effective. It is one of five Centers at the United States Food and Drug Administration. ) scientists and reviewers in a range of toxicogenomics applications and is used by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. to evaluate voluntarily genomic data submissions. The company has major research collaborations and technology alliances with Bristol Myers Squibb, Abbott Laboratories Abbott Laboratories (NYSE: ABT) is a diversified pharmaceuticals and health care company. It has over 65,000 employees and operates in 130 countries. The corporate headquarters are in Abbott Park, Illinois, a neighborhood of North Chicago, Illinois. and Eli Lilly Eli Lilly can refer to:
Headquartered in Mountain View, California For the census-designated place, see Mountain View, Contra Costa County, California. For other places called "Mountain View", see . Mountain View is a city in Santa Clara County, in the U.S. state of California. The city gets its name from the views of the Santa Cruz Mountains. , Iconix was founded in 1998 and is privately held. For more information, visit www.iconixbiosciences.com About Affymetrix Affymetrix scientists invented the world's first high-density microarray in 1989 and began selling the first commercial microarray in 1994. Since then, Affymetrix GeneChip([R]) technology has become the industry standard in molecular biology molecular biology, scientific study of the molecular basis of life processes, including cellular respiration, excretion, and reproduction. The term molecular biology was coined in 1938 by Warren Weaver, then director of the natural sciences program at the Rockefeller research. Affymetrix technology is used by the world's top pharmaceutical, diagnostic and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. as well as leading academic, government and not-for-profit research institutes. More than 1,400 systems have been installed around the world and more than 7,000 peer-reviewed papers have been published using the technology. Affymetrix' patented photolithographic pho·to·li·thog·ra·phy n. A planographic printing process using plates made according to a photographic image. pho manufacturing process provides the most information capacity available today on an array, enabling researchers to use a whole-genome approach to analyzing the relationship between genetics and health. Affymetrix is headquartered in Santa Clara, Calif., with manufacturing facilities in Sacramento, Calif., and Bedford, Mass. The company maintains important sales and marketing operations in Europe and Asia, and has about 1,100 employees worldwide. For more information about Affymetrix, please visit the company's website at www.affymetrix.com. All statements in this press release that are not historical are "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act as amended, including statements regarding Affymetrix' "expectations," "beliefs," "hopes," "intentions," "strategies" or the like. Such statements are subject to risks and uncertainties that could cause actual results to differ materially for Affymetrix from those projected, including, but not limited to: risks and uncertainties associated with the commercial success of the ToxFX Analysis Suite discussed in this press release; risks of the company's ability to achieve and sustain higher levels of revenue, higher gross margins and reduced operating expenses Operating expenses The amount paid for asset maintenance or the cost of doing business, excluding depreciation. Earnings are distributed after operating expenses are deducted. ; uncertainties relating to relating to relate prep → concernant relating to relate prep → bezüglich +gen, mit Bezug auf +acc technological approaches, manufacturing and product development; personnel retention; uncertainties related to cost and pricing of Affymetrix products; dependence on collaborative partners; uncertainties relating to sole source suppliers; uncertainties relating to FDA and other regulatory approvals; competition; risks relating to intellectual property of others and the uncertainties of patent protection and litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. . These and other risk factors are discussed in Affymetrix' Form 10-K/A for the year ended December 31, 2005, and other SEC reports, including its Quarterly Reports on Form 10-Q Form 10-Q See 10-Q. for subsequent quarterly periods. Affymetrix expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Affymetrix' expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based. NOTE: Affymetrix, the Affymetrix logo and GeneChip are registered trademarks owned or used by Affymetrix Inc. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion